p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.

Aromatase inhibitors have played a central role in endocrine therapy for estrogen receptor (ER)-positive breast cancer in postmenopausal women. However, factors predictive of the efficacy of aromatase inhibitors, and prognostic factors, both for early and late recurrence in women treated with adjuvant aromatase inhibitors have not been identified. Whole genome analysis identified that a TP53 gene mutation exists in ER-positive breast cancers, although the frequency of TP53 gene mutation in luminal tumors is lower compared with basal-like or human epidermal growth factor receptor type 2 (HER2)-positive breast cancers. We examined expression of p53, as well as ER, progesterone receptor, HER2 and Ki-67 using immunohistochemistry in postmenopausal ER-positive breast cancer patients who were treated with aromatase inhibitors as adjuvant endocrine therapy. There were 53 (21%) tumors that contained 10% or more p53-positive cells. High p53 expression was positively correlated with tumor grade, HER2 score and Ki-67 expression. Significant association was observed between disease-free survival and high p53 expression in multivariate analysis (P < 0.0001). Compared with women without recurrence, women with early recurrence had significantly higher p53 expression (P < 0.0001), as did women with late recurrence (P = 0.037). The present study demonstrates that p53 accumulation is a strong predictor of both early and late recurrence in ER-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy. TP53 gene alteration might be a key biological characteristic of ER-positive breast cancer.

Yamamoto M ，Hosoda M ，Nakano K ，Jia S ，Hatanaka KC ，Takakuwa E ，Hatanaka Y ，Matsuno Y ，Yamashita H ... -  《-》

High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.

Endo Y ，Toyama T ，Takahashi S ，Sugiura H ，Yoshimoto N ，Iwasa M ，Kobayashi S ，Fujii Y ，Yamashita H ... -  《-》

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.

Kurozumi S ，Matsumoto H ，Inoue K ，Tozuka K ，Hayashi Y ，Kurosumi M ，Oyama T ，Fujii T ，Horiguchi J ，Kuwano H ... -  《PLoS One》

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.

Yamashita H ，Ogiya A ，Shien T ，Horimoto Y ，Masuda N ，Inao T ，Osako T ，Takahashi M ，Endo Y ，Hosoda M ，Ishida N ，Horii R ，Yamazaki K ，Miyoshi Y ，Yasojima H ，Tomioka N ，Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society ... -  《-》

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.

Luen SJ ，Asher R ，Lee CK ，Savas P ，Kammler R ，Dell'Orto P ，Biasi OM ，Demanse D ，JeBailey L ，Dolan S ，Hackl W ，Thuerlimann B ，Viale G ，Colleoni M ，Regan MM ，Loi S ... -  《-》